Jan Hartmann: FDA Has Approved An Expanded Indication for Haemonetics VASCADE MVP XL
Jan Hartmann, Chief Medical Officer at Haemonetics, shared on LinkedIn:
”Happy to share an important milestone for VASCADE MVP®XL.
The U.S. FDA has approved an expanded indication for Haemonetics MVP®XL, supporting venous closure for procedures using up to 17F outer diameter sheaths, including use with leading PFA and LAAC technologies – allowing more patients to benefit from the unique extravascular design and performance of MVP® XL.
The approval was supported by data from the AMBULATE EXPAND pivotal trial, which demonstrated:
- 0% major access‑site closure–related complications
- 0% minor access‑site closure–related complications
- Median time to ambulation of 2.4 hours
- Median time to hemostasis of 2.3 minutes
These results underscore the clinical value of reliable, large‑bore venous closure.
A sincere thank you to the patients who participated in the clinical trial, and to the investigators and site teams whose rigorous work provided this important evidence.
The pivotal trial results were presented at AF Symposium 2026 in Boston earlier this year, with the ultrasound substudy data to be shared at the Heart Rhythm Society meeting next month in Chicago.
Proud of the clinical science and teamwork behind this advancement!”
Title: Safety and Efficacy of the VASCADE MVP® XL Venous Vascular Closure System for Management of Femoral Venotomy Following Catheter-Based Interventions Utilizing 16-17F OD Sheaths: The AMBULATE EXPAND Trial
Authors: Hugh Thomas McElderry, Amin Al-Ahmad, David De Lurgio, T. Jared Bunch, Zayd A. Eldadah, Maheer Gandhavadi, Bruce Hook, Joseph Banno, Suneet Mittal
Read the Full Article on Journal of Cardiovascular Electrophysiology
Stay updated on all scientific advances with Hemostasis Today.
-
May 13, 2026, 17:38Rohit Sankar J. Snscphysio: Recognizing the Clot Before It Becomes Life-Threatening
-
May 13, 2026, 16:41Seema Dawood: When Elevated Platelets Signal a Myeloproliferative Neoplasm
-
May 13, 2026, 16:38Kari Tikkinen: Defining Thromboprophylaxis in MIBC Neoadjuvant Care
-
May 13, 2026, 16:28Nadia Tarhini: Evaluating the Risk of Recurrent Thrombosis in Children with ALL
-
May 13, 2026, 16:01Sifat Jubaira: When Low MCV Meets High Platelets
-
May 13, 2026, 15:58Aktham El-rekaby: Immunothrombosis in Acute Ischaemic Stroke
-
May 13, 2026, 15:49Alison Dougall: Oral Health and Cardiovascular Risk in Bleeding Disorders
-
May 13, 2026, 15:38International Journal of Stroke: Oral Anticoagulants and DOAC–Antiplatelet Therapy Are Associated with Increased Major Bleeding Risk
-
May 13, 2026, 15:19Papa Heme։ Causes of Isolated Prolonged aPTT Without Bleeding